Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the bi-specific mabs market right now?

Over the previous years, the market size of bi-specific MAbS has witnessed a swift expansion. The market value is projected to rise from $7.83 billion in 2024 to $9.1 billion in 2025, translating to a compound annual growth rate (CAGR) of 16.2%. Factors contributing to this growth during the historical period include elevated healthcare spending, augmented funding, and government interventions.

How fast Is the bi-specific mabs market expected to grow, and what’s its future value?

In the coming years, the bi-specific MAbS market is forecasted to experience an accelerated pace of expansion. The market is set to reach a whopping $15.19 billion by the year 2029, representing a compound annual growth rate (CAGR) of 13.7%. Factors believed to contribute to this escalated growth within the projected time frame include the rising incidence of cancer, population aging, and an increased prevalence of chronic illnesses. Key trends projected for this period include an emphasis on technological advancements, product innovation, the use of artificial intelligence, investments in targeted and combination therapy, as well as the formation of strategic partnerships.

Get your bi-specific mabs market report here!

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

What are the leading drivers of growth in the bi-specific mabs market?

Forecasted growth in the bispecific monoclonal antibodies market is expected due to the rise in prevalence of cancer and other chronic illnesses. These antibodies are specially engineered for targeting various health conditions including cancers, infectious ailments, disorders of the central nervous system, and autoimmune diseases. The advantage of bispecific monoclonal antibodies over monoclonal antibodies is their ability to target two or more antigens on cells, thus inhibiting the progress of cancer. For example, as per the Cancer Facts & Figures 2023 report by the American Cancer Society, a voluntary health organization based in the US, it is predicted that there will be around 609,820 cancer fatalities in the USA in 2023. Therefore, owing to the expected rise in chronic illnesses, most notably cancer, the requirement for bi-specific MAbs, which are highly effective in treating these conditions, is projected to surge.

What are the key segments defining the bi-specific mabs market?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Who are the key players steering the development of the bi-specific mabs market?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

What emerging trends are influencing the growth of the bi-specific mabs market?

In an effort to broaden their product range and global reach, companies in the bi-specific MAbs market are increasingly pursuing strategic avenues such as collaborations and partnerships. A strategic collaboration comprises a mutual partnership between two or more organizations with the objective of fulfilling shared aims or goals. One such example is the exclusive partnership in October 2022 between Gilead Sciences and MacroGenics, both US-based biopharmaceutical companies. This collaboration involved the development of MGD024, a bispecific antibody targeting CD123 and CD3. The partnership also included two other bispecific research programs. This development bestowed exclusive rights to Gilead to license MGD024, which holds promise as a treatment for various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to reduce cytokine-release syndrome (CRS) and allows for intermittent dosage, potentially making treatment more comfortable for patients and improving clinical outcomes for individuals suffering from AML and MDS.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

Which regions are most influential in expanding the bi-specific mabs market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Microbiome Therapeutics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: